//16 Jun 2011
At the 6th International Symposium on Emerging and Re-emerging Pig Diseases, held in Barcelona, Spain, Intervet/Schering-Plough Animal Health introduced BacuCheck, a simple ELISA test for confirmation of vaccination status with the company’s vaccine Porcilis PCV.
The test is an easy-to-use and value-added herd monitoring service for pig farmers and traders and was developed to be able to discriminate PCV2-vaccinated piglets from non-vaccinated animals. The test is also able to verify if the animals have received the full vaccine dose.
The test detects antibodies against baculomarkers which are used in the production of the structural capsid protein ORF2 component of the vaccine, and are thus able to differentiate between the field virus and the vaccine antigen. By using this laboratory test, piglet producers and traders are able to certify PCV2-vaccinated piglets as an additional quality stamp, thereby facilitating the building of trustful business relationships with feeding pig companies.
Test results
Alex Eggen, global technical director of the company’s Swine Business Unit, explains the scope and interpretation of the test: "Insufficient dosing will provide test results that indicate that pigs are not or not properly vaccinated […]."
He added that the test results are valid for this specific brand of PCV vaccine only. He said, "As the system was not tested on samples originating from pigs vaccinated with other PCV2 vaccines, BacuCheck can not reliably be used to control the vaccination status of animals vaccinated with vaccines other than Porcilis PCV."
The company developed BacuCheck in collaboration with veterinary diagnostic laboratory Synlab vet, located in Leipzig, Germany.
The test has already been rolled out in Germany; a launch is imminent in the Netherlands, Denmark, Belgium, Austria, Italy and Spain. Other markets will see implementation before the end of this year.
Related websites:
• Intervet/Schering-Plough Animal Health
• Sixth International Symposium on Emerging and Re-emerging Pig Diseases
Showing posts with label Intervet/SP. Show all posts
Showing posts with label Intervet/SP. Show all posts
13 May 2011
Intervet/SP launches new atrophic rhinitis vaccine for pigs
//12 May 2011
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
Subscribe to:
Posts (Atom)